Next Article in Journal
Diamidines versus Monoamidines as Anti-Pneumocystis Agents: An in Vivo Study
Previous Article in Journal
Voltage-Gated Calcium Channel Antagonists and Traumatic Brain Injury
Previous Article in Special Issue
The Liver as a Target Organ for Gene Therapy: State of the Art, Challenges, and Future Perspectives
Pharmaceuticals 2013, 6(7), 813-836; doi:10.3390/ph6070813
Review

Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy

*  and
Received: 13 May 2013; in revised form: 14 June 2013 / Accepted: 14 June 2013 / Published: 27 June 2013
(This article belongs to the Special Issue Gene Therapy)
View Full-Text   |   Download PDF [682 KB, uploaded 27 June 2013]   |   Browse Figures
Abstract: Various characteristics of adeno-associated virus (AAV)-based vectors with long-term safe expression have made it an exciting transduction tool for clinical gene therapy of Duchenne muscular dystrophy (DMD). Although host immune reactions against the vector as well as transgene products were detected in some instances of the clinical studies, there have been promising observations. Methods of producing AAV vectors for considerable in vivo experimentation and clinical investigations have been developed and a number of studies with AAV vector-mediated muscle transduction were attempted. Notably, an intravenous limb perfusion transduction technique enables extensive transgene expression in the skeletal muscles without noticeable adverse events. Furthermore, cardiac transduction by the rAAV9-microdystrophin would be promising to prevent development of cardiac dysfunction. Recent achievements in transduction technology suggest that long-term transgene expression with therapeutic benefits in DMD treatment would be achieved by the rAAV-mediated transduction strategy with an adequate regimen to regulate host immune response.
Keywords: DMD; AAV; immune response DMD; AAV; immune response
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Okada, T.; Takeda, S. Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy. Pharmaceuticals 2013, 6, 813-836.

AMA Style

Okada T, Takeda S. Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy. Pharmaceuticals. 2013; 6(7):813-836.

Chicago/Turabian Style

Okada, Takashi; Takeda, Shin'ichi. 2013. "Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy." Pharmaceuticals 6, no. 7: 813-836.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert